Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Tafenoquine (Krintafel) is used for the radical cure of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate therapy for acute P. vivax infection.
• The information was synthesized from a total of 8 systematic reviews/meta-analyses, which provided a comprehensive overview of tafenoquine's pharmacodynamics, comparative efficacy and safety analyses, and considerations for specific patient subgroups.
• In terms of adherence to the treatment regimen, tafenoquine offers an advantage over primaquine due to its single-dose administration, as opposed to primaquine's standard 14-day regimen.
• Efficacy comparison between tafenoquine and primaquine suggests that at doses above 300 mg, tafenoquine significantly reduces relapse rates over a six-month follow-up period; this could be more effective than the standard primaquine regimen according to some studies.
• Safety concerns exist for both drugs, but serious adverse events seem comparable between them for patients with normal G6PD status; however, inadvertent administration of tafenoquine - due to its long half-life - poses significant risks, especially among individuals with G6PD deficiency.
• There is limited data on the drug’s efficacy and safety in children under age sixteen or pregnant women, hence further research should aim at addressing these gaps while also focusing on those with G6PD deficiency.